BRPI0611613A2 - tetraidroquinolinas substituìdas - Google Patents

tetraidroquinolinas substituìdas Download PDF

Info

Publication number
BRPI0611613A2
BRPI0611613A2 BRPI0611613-2A BRPI0611613A BRPI0611613A2 BR PI0611613 A2 BRPI0611613 A2 BR PI0611613A2 BR PI0611613 A BRPI0611613 A BR PI0611613A BR PI0611613 A2 BRPI0611613 A2 BR PI0611613A2
Authority
BR
Brazil
Prior art keywords
formula
denotes
aryl
original document
document page
Prior art date
Application number
BRPI0611613-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Kai Schiemann
Ulrich Emde
Dirk Finsinger
Christiane Amendt
Nina Heiss
Frank Zenke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0611613A2 publication Critical patent/BRPI0611613A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0611613-2A 2005-06-13 2006-05-17 tetraidroquinolinas substituìdas BRPI0611613A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005027170.7 2005-06-13
DE102005027170A DE102005027170A1 (de) 2005-06-13 2005-06-13 Substituierte Tetrahydrochinoline
PCT/EP2006/004656 WO2007054138A1 (de) 2005-06-13 2006-05-17 Substituierte tetrahydrochinoline

Publications (1)

Publication Number Publication Date
BRPI0611613A2 true BRPI0611613A2 (pt) 2010-09-21

Family

ID=36699028

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611613-2A BRPI0611613A2 (pt) 2005-06-13 2006-05-17 tetraidroquinolinas substituìdas

Country Status (15)

Country Link
US (1) US7893082B2 (enExample)
EP (1) EP1891076B1 (enExample)
JP (1) JP5180070B2 (enExample)
KR (1) KR20080030015A (enExample)
CN (2) CN101198613A (enExample)
AR (1) AR054616A1 (enExample)
AU (1) AU2006312800B2 (enExample)
BR (1) BRPI0611613A2 (enExample)
CA (1) CA2611889C (enExample)
DE (1) DE102005027170A1 (enExample)
ES (1) ES2566729T3 (enExample)
MX (1) MX2007015782A (enExample)
RU (1) RU2007147925A (enExample)
WO (1) WO2007054138A1 (enExample)
ZA (1) ZA200800365B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102007013855A1 (de) * 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
CL2008003063A1 (es) 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
AU2008338015B2 (en) * 2007-12-18 2013-03-07 Merck Patent Gmbh Process for preparing tetrahydroquinoline derivatives
WO2019089412A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CA3201443A1 (en) 2020-12-25 2022-06-30 Toray Industries, Inc. Tetrahydroquinoline derivative and medicinal use thereof
KR20250026152A (ko) 2022-06-24 2025-02-25 도레이 카부시키가이샤 근위축성 측색경화증의 치료제 또는 예방제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946556A4 (en) * 1996-12-18 2001-07-04 Lilly Co Eli COMBINATORY METHOD FOR THE PREPARATION OF TETRAHYDROQUINOLEIN BANKS
US6288075B1 (en) * 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
US7250423B2 (en) * 2001-09-24 2007-07-31 Chao-Jun Li Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers
WO2005016255A2 (en) * 2003-07-16 2005-02-24 Ligand Pharmaceuticals Incorporated Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
EP2033959B1 (de) * 2003-12-20 2011-04-27 Merck Patent GmbH Tetrahydropyranochinolinderivate
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
MXPA06012323A (es) * 2004-04-28 2007-01-17 Takeda Pharmaceutical Derivado de quinolina fusionada y uso del mismo.
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
MX2008016071A (es) * 2006-06-19 2009-01-15 Merck Patent Gmbh Formas polimorficas y proceso.

Also Published As

Publication number Publication date
CN102010416A (zh) 2011-04-13
CA2611889C (en) 2013-05-14
EP1891076A1 (de) 2008-02-27
KR20080030015A (ko) 2008-04-03
AU2006312800B2 (en) 2011-08-25
JP5180070B2 (ja) 2013-04-10
DE102005027170A1 (de) 2006-12-14
US7893082B2 (en) 2011-02-22
US20080194615A1 (en) 2008-08-14
WO2007054138A1 (de) 2007-05-18
ZA200800365B (en) 2009-05-27
AU2006312800A1 (en) 2007-05-18
CN101198613A (zh) 2008-06-11
MX2007015782A (es) 2008-02-22
ES2566729T3 (es) 2016-04-15
CA2611889A1 (en) 2007-05-18
JP2008545803A (ja) 2008-12-18
EP1891076B1 (de) 2016-01-27
RU2007147925A (ru) 2009-07-20
AR054616A1 (es) 2007-07-04

Similar Documents

Publication Publication Date Title
JP2010513335A (ja) 有糸分裂モータータンパク質(mitoticmotorprotein)の調節剤としてのテトラヒドロベンゾイソオキサゾールおよびテトラヒドロインダゾール誘導体
JP5237555B2 (ja) 2−(ヘテロ)アリール置換テトラヒドロキノリン誘導体
JP5847226B2 (ja) 腫瘍の治療のためのピペリジンおよびピペラジン誘導体
JP2008542215A (ja) キナゾリノン
JP5480636B2 (ja) 置換テトラヒドロキノリン類
KR20090130071A (ko) 테트라히드로퀴놀린 유도체 및 암 치료를 위한 이의 용도
BRPI0611613A2 (pt) tetraidroquinolinas substituìdas
JP5420898B2 (ja) 有糸分裂モータータンパク質eg5の調節剤の形態で使用されるテトラヒドロキノリン
JP5113035B2 (ja) フタラジノン
JP5180071B2 (ja) テトラヒドロキノリン誘導体
JP5121450B2 (ja) テトラヒドロキノリン
BRPI0620090A2 (pt) diazepinonas
JP2010521504A (ja) 置換テトラヒドロピロロキノリン類
CN100567289C (zh) 2-(杂)芳基-取代的四氢喹啉衍生物
JP2008531612A (ja) インダン
KR101211973B1 (ko) 2-(헤테로)-아릴-치환 테트라하이드로퀴놀린 유도체
JP2007536306A (ja) ジヒドロベンゾチオフェン類
HK1096395B (en) 2-(hetero)aryl-substituted tetrahydroquinoline derivatives
HK1141014A (en) Substituted tetrahydroquinolines
DE102004026026A1 (de) Tetrahydrochinoline
HK1120797A (en) Substituted tetrahydroquinolines

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A, ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2212 DE 28/05/2013.